19.5 million Vaccinated with MenAfriVac

Since September 2010, a total of 19.5 million people have been immunized against serogroup A meningitis with MenAfriVac, the meningococcal A conjugate vaccine developed through the Meningitis Vaccine Project.

MenAfriVac, produced by the Serum Institute of India Ltd, is priced at less that US$0.50 a dose and has been hailed as an affordable solution to one of the most serious health concerns in Sub-Saharan Africa.

Pending adequate funding, the Meningitis Vaccine Project and its partners hope to vaccinate some 300 million people throughout the African meningitis belt by 2015.